These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24636625)
1. Improving access to vaccines through tiered pricing. Berkley S Lancet; 2014 Jun; 383(9936):2265-7. PubMed ID: 24636625 [No Abstract] [Full Text] [Related]
2. Vaccines as a global imperative--a business perspective. Stéphenne J Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955 [TBL] [Abstract][Full Text] [Related]
3. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature. Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063 [TBL] [Abstract][Full Text] [Related]
4. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
5. Price transparency is a step towards sustainable access in middle income countries. Cernuschi T; Gilchrist S; Hajizada A; Malhame M; Mariat S; Widmyer G BMJ; 2020 Jan; 368():l5375. PubMed ID: 31932333 [No Abstract] [Full Text] [Related]
8. Medicine. The intangible value of vaccination. Rappuoli R; Miller HI; Falkow S Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712 [No Abstract] [Full Text] [Related]
9. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways]. Crager SE Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189 [TBL] [Abstract][Full Text] [Related]
10. Drugs and vaccines around the world. Health Aff (Millwood); 2006; 25(2):312. PubMed ID: 16522572 [No Abstract] [Full Text] [Related]
11. Protecting research and a case for optimism. Gates B Sci Transl Med; 2013 Dec; 5(214):214ed21. PubMed ID: 24307689 [No Abstract] [Full Text] [Related]
12. Africa could learn from India's burgeoning pharma sector. Selvaraj S BMJ; 2013 Aug; 347():f4235. PubMed ID: 23913693 [No Abstract] [Full Text] [Related]
13. Market-based licensing for HPV vaccines in developing countries. Outterson K; Kesselheim AS Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488 [TBL] [Abstract][Full Text] [Related]
14. The problems and promise of vaccine markets in developing countries. Batson A Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160 [TBL] [Abstract][Full Text] [Related]
15. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States. Shen AK; Rodewald LE; Birkhead GS Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586 [TBL] [Abstract][Full Text] [Related]
16. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain. James JS AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151 [TBL] [Abstract][Full Text] [Related]
17. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries. Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824 [No Abstract] [Full Text] [Related]
18. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Jadhav S; Datla M; Kreeftenberg H; Hendriks J Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742 [TBL] [Abstract][Full Text] [Related]
19. Defining the concept of fair pricing for medicines. Moon S; Mariat S; Kamae I; Pedersen HB BMJ; 2020 Jan; 368():l4726. PubMed ID: 31932334 [No Abstract] [Full Text] [Related]
20. Ethics and AIDS drugs. Dowell W Time; 1999 Jul; 154(2):49. PubMed ID: 10538646 [No Abstract] [Full Text] [Related] [Next] [New Search]